Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the 12-month outcome of intravitreal anti-vascular endothelial growth factor therapy ineyes with bilateral retinal angiomatous proliferation (RAP). Methods: This retrospective observational study included 38 eyes of 19 patients with stage 1 or 2 bilateralRAP at diagnosis. The eyes of patients who exhibited different baseline best-corrected visual acuity (BCVA)values in both eyes were assigned to one of two groups—the better (n = 13) and worse (n = 13) visual acuitygroups. The BCVA values in both groups were compared to those at baseline and at 12 months. In addition,the 12-month changes in BCVA were compared between the two groups. The association between the opticalcoherence tomography findings at diagnosis and the 12-month BCVA was also analyzed. Results: The values of mean baseline and 12-month BCVA in the better visual acuity group (13 eyes) were 0.48± 0.19 and 0.58 ± 0.29, respectively, and those in the worse visual acuity group (13 eyes) were 0.83 ± 0.20 and0.90 ± 0.31. The 12-month changes in BCVA were not significantly different between the two groups (p = 0.786). Among the six patients with equivalent baseline BCVA in both eyes, four patients (66.7%) exhibited 1 to 2 linesor ≥3 lines of difference in BCVA between eyes at 12 months. Eyes without pigment epithelial detachment (PED)at diagnosis exhibited significantly better BCVA at 12 months than eyes with PED (p = 0.021). Conclusions: Better baseline visual acuity was associated with better BCVA at 12 months posttreatment in patientswith bilateral RAP. However, equivalent baseline visual acuity in both eyes might not guarantee similartreatment outcomes. In addition, the absence of PED is predictive of better visual outcome.
Abstract
Purpose: To evaluate the 12-month outcome of intravitreal anti-vascular endothelial growth factor therapy ineyes with bilateral retinal angiomatous proliferation (RAP). Methods: This retrospective observational study included 38 eyes of 19 patients with stage 1 or 2 bilateralRAP at diagnosis. The eyes of patients who exhibited different baseline best-corrected visual acuity (BCVA)values in both eyes were assigned to one of two groups—the better (n = 13) and worse (n = 13) visual acuitygroups. The BCVA values in both groups were compared to those at baseline and at 12 months. In addition,the 12-month changes in BCVA were compared between the two groups. The association between the opticalcoherence tomography findings at diagnosis and the 12-month BCVA was also analyzed. Results: The values of mean baseline and 12-month BCVA in the better visual acuity group (13 eyes) were 0.48± 0.19 and 0.58 ± 0.29, respectively, and those in the worse visual acuity group (13 eyes) were 0.83 ± 0.20 and0.90 ± 0.31. The 12-month changes in BCVA were not significantly different between the two groups (p = 0.786). Among the six patients with equivalent baseline BCVA in both eyes, four patients (66.7%) exhibited 1 to 2 linesor ≥3 lines of difference in BCVA between eyes at 12 months. Eyes without pigment epithelial detachment (PED)at diagnosis exhibited significantly better BCVA at 12 months than eyes with PED (p = 0.021). Conclusions: Better baseline visual acuity was associated with better BCVA at 12 months posttreatment in patientswith bilateral RAP. However, equivalent baseline visual acuity in both eyes might not guarantee similartreatment outcomes. In addition, the absence of PED is predictive of better visual outcome.
참고문헌 (32)
- Yannuzzi LA, "Retinal angiomatous proliferation in age-related macular degeneration", Retina, 21, pp.416~434 (2001)
- Gross NE, "Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation", Retina, 25, pp.713~718 (2005)
- Campa C, "Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation", Eye (Lond), 24, pp.1585~1589 (2010)
- Sawa M, "Incidence and characteristics of neovascularization in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation", Retina, 34, pp.761~767 (2014)
- Chang YS, "Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population", Acta Ophthalmol, 94, pp.e49~e53 (2016)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Kang S, "One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups", Jpn J Ophthalmol, 53, pp.389~395 (2009)
- 장용석, "Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity", Korean Journal of Ophthalmology, 28(6), pp.466~472 (2014), 대한안과학회
- Sun Young Lee, "The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy", Korean Journal of Ophthalmology, 22(2), pp.92~99 (2008), 대한안과학회
- Hemeida TS, "Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation", Br J Ophthalmol, 94, pp.701~705 (2010)
- Gharbiya M, "Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen", Retina, 34, pp.298~305 (2014)
- Parodi MB, "Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation", Acta Ophthalmol, 91, pp.267~273 (2013)
- Inoue M, "Longterm results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography", Br J Ophthalmol, 98, pp.956~960 (2014)
- Rouvas AA, "Longterm results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation", Retina, 32, pp.1181~1189 (2012)
- Lai TY, "Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration", Graefes Arch Clin Exp Ophthalmol, 245, pp.1877~1880 (2007)
- Reche-Frutos J, "Ranibizumab in retinal angiomatous proliferation (RAP):influence of RAP stage on visual outcome", Eur J Ophthalmol, 21, pp.783~788 (2011)
- Konstantinidis L, "Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP)", Graefes Arch Clin Exp Ophthalmol, 247, pp.1165~1171 (2009)
- Jae Hoon Kang, "Retinal Angiomatous Proliferation and Intravitreal Bevacizumab Injection", Korean Journal of Ophthalmology, 21(4), pp.213~215 (2007), 대한안과학회
- Cohen SY, "Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation", Br J Ophthalmol, 91, pp.354~359 (2007)
- Ueda-Arakawa N, "Prevalence and genomic association of reticular pseudodrusen in age-related macular degeneration", Am J Ophthalmol, 155, pp.260.e2~269.e2 (2013)
- Kim JH, "Prevalence of subtypes of reticular pseudodrusen in newly diagnosed exudative age-related macular degeneration and polypoidal choroidal vasculopathy in Korean patients", Retina, 35, pp.2604~2612 (2015)
- Haas P, "Choroidal thickness in patients with reticular pseudodrusen using 3D 1060-nm OCT maps", Invest Ophthalmol Vis Sci, 55, pp.2674~2681 (2014)
- Ueda-Arakawa N, "Macular choroidal thickness and volume of eyes with reticular pseudodrusen using swept-source optical coherence tomography", Am J Ophthalmol, 157, pp.994~1004 (2014)
- Kang HM, "Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration", Am J Ophthalmol, 157, pp.1013~1021 (2014)
- Jonas JB, "Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration:effect of baseline visual acuity", J Ocul Pharmacol Ther, 27, pp.401~405 (2011)
- Matsumoto H, "Tomographic features of intraretinal neovascularization in retinal angiomatous proliferation", Retina, 30, pp.425~430 (2010)
- Rouvas AA, "Angiographic and OCT features of retinal angiomatous proliferation", Eye (Lond), 24, pp.1633~1642 (2010)
- Kim JH, "Diagnosis of type 3neovascularization based on optical coherence tomography images", Retina, 36, pp.1506~1515 (2016)
- Kim JH, "Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration", Am J Ophthalmol, 155, pp.743.e1~749.e2 (2013)
- Schmidt-Erfurth U, "A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration", Prog Retin Eye Res, 50, pp.1~24 (2016)
- Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)